Amyloidosis Center News
National Doctor’s Day
Today is National Doctors’ Day, and we’d like to take a moment to say thank you to the incredible physicians that make up our Multidisciplinary Team at the BU Amyloidosis Center! #nationaldoctorsday #amyloidosis
Congratulations Dr. Siddiqi!
The outstanding service of Dr. Omar Siddiqi has been honored by The Boston University School of Medicine with the "Educator of the Year" award! Congratulations Dr. Siddiqi!
Intellia’s first CRISPR gene editing therapy shows promise in small study
"Intellia Therapeutics has moved one step closer to its ambition of creating one-and-done gene-editing treatments for people with genetic diseases. Last August, the Cambridge company and its partner, Regeneron Pharmaceuticals, published a landmark study showing that even low doses of their one-time treatment based on CRISPR-Cas9 technology could dramatically reduce... More
Amyloidosis Foundation Grant!
Congratulations to Dr. K. H. Vincent Lau and mentor Dr. Vaishali Sanchorawala on their Amyloidosis Foundation Grant award, announced by the foundation on January 31, 2022! Their project "Evaluating Plasma Neurofilament Light Chain as an Early Biomarker for Polyneuropathy in V122I Hereditary Transthyretin Amyloidosis" aims to characterize a blood marker... More
Congratulations to Dr. Andrea Havasi on her recent promotion to Associate Professor of Medicine.
BU Amyloidosis Center receives grant to develop new amyloid diagnostics
The Amyloidosis Center has been awarded a $250,000 grant from the Improving Diagnosis of AL Amyloidosis (IDEA) QuickFire Challenge, run by the pharmaceutical company Johnson & Johnson (J&J) innovation/JLabs. The research, led by Dr. Gareth Morgan, will develop new approaches to identify individuals at risk of AL amyloidosis, and also... More
Congratulations to Dr. Andrea Havasi on her recent promotion to Associate Professor of Medicine.
Andrea Havasi, BUSM, Nephrology, specializes in the kidney complications of amyloidosis. Her earliest post-doctoral studies focused on ischemic renal tubular cell injury that led to subsequent studies on the harmful effects of proteinuria on renal tubular function and her current research on the toxic effects of immunoglobulin light-chains in patients... More
Congratulations to our director, Dr. Vaishali Sanchorawala
Congratulations to our director, Dr. Vaishali Sanchorawala, who has been selected for membership to the BUMG Clinical Excellence Society. The BUMG Clinical Excellence Society was established in 2017 to recognize the highest level of clinical excellence. Dr. Sanchorawala was selected for this honor as she attained finalist status in the... More
Dr. John Berk the Assistant Director of the Amyloidosis Center
John Berk, MD, Assistant Director of the center, specializes in familial transthyretin and lung amyloidosis. Dr. Berk designed and conducted the first international randomized controlled trial for familial amyloid polyneuropathy. This NIH- and FDA-funded study found that Diflunisal, an obsolete non-steroidal anti-inflammatory drug, inhibited neurologic disease progression, validated a neurologic... More
U.S. Senate Committee on Appropriations: Amyloidosis Language
HOUSE APPROPRIATIONS COMMITTEE FISCAL YEAR 2022 LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION AMYLOIDOSIS REPORT LANGUAGE H. Rpt. 117-96 (accompany H.R. 4502) July 19, 2021 TITLE II—DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH OFFICE OF THE DIRECTOR (OD) Amyloidosis.—The Committee directs NIH to continue its expansion of research efforts in amyloidosis, a group of rare diseases... More